RxDoctor Payments DataLook up a doctor →

Aaron Fuchs, MD

Procedural Dermatology · Falls Church, VANPI 1124261177

Payments from drug & device makers

$375,712in general payments, 2019–2025

Across 1,541 payments — averaging $243.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$68K
  • Lilly USA, LLC$65K
  • Dermavant Sciences, Inc.$65K
  • Pfizer$60K
  • Galderma Laboratories, L.p.$32K
  • Novartis$29K
  • plus $57K from 35 others

What the payments were for

  • Consulting fees$33,0179%
  • Speaking & faculty fees$303,94581%
  • Travel & lodging$10,0323%
  • Food & beverage$28,3238%
  • Education$3950%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few procedural dermatology providers in Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$857,848
Medicare patients
2,312
Services billed
12,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab111$427,344
TremfyaGuselkumab15$202,981
Humira PenAdalimumab13$90,734
Humira(Cf) PenAdalimumab13$88,525
Dupixent SyringeDupilumab13$57,382
Doxycycline Ir-DrDoxycycline Monohydrate39$26,787
JubliaEfinaconazole16$22,680
Pimecrolimus42$10,467
Fluocinonide206$9,974
Clobetasol Propionate116$7,294
Tretinoin MicrosphereTretinoin Microspheres18$5,526
Betamethasone Valerate21$4,413
Ivermectin20$4,329
Triamcinolone Acetonide279$3,447
Tacrolimus16$3,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$2,641$202,98115 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$15,390$22,68016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few procedural dermatology providers in Virginiaon file to place this against a meaningful peer group, so we don't.

Other procedural dermatology in Falls Church

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →